APRE-DDRi

N/A

Report date: 2023/09/22 10:49:02
NME

Base Information

Drug NameAPRE-DDRi
Drug Alias NameAtaxia telangiectasia and Rad3-related protein inhibitorsATRN-502ATRN-507ATRN-212
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA repair inhibitorsSerine-protein kinase ATR inhibitors
TargetsSerine-protein kinase ATR
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAprea Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAprea Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A